美国为开发巴西利的口服抗生素用于抗药性尿道感染提供1.59亿美元资金. U.S. funds $159M to develop Basilea’s oral antibiotic for drug-resistant urinary infections.

Basilea Pharmaceutica 已从美国政府 BARDA 获得一份价值 1.59 亿美元的合同，用于开发其研究性口服抗生素头孢替布腾-ledaborbactam etzadroxil，用于治疗复杂尿路感染，包括肾脏感染。 Basilea Pharmaceutica has secured a $159 million contract from the U.S. government’s BARDA to develop its investigational oral antibiotic ceftibuten-ledaborbactam etzadroxil for complicated urinary tract infections, including kidney infections. 该药物旨在治疗抗多种药物的抗克菌阴性细菌,现已获得林业发展局快速道和QIDP指认。 The drug, designed to treat multidrug-resistant Gram-negative bacteria, has received FDA Fast Track and QIDP designations. 其目的是恢复氯丁二烯抗抗药性菌株的效力,目前正通过第三阶段试验予以推进。 It aims to restore effectiveness of ceftibuten against resistant strains and is being advanced through Phase 3 trials. 这笔资金最初为600万美元,是里程碑式付款,用于支持为难以治疗的感染制定关键的口服治疗方案。 The funding, with an initial $6 million and milestone-based payments, supports the development of a critical oral treatment option for hard-to-treat infections.